about
mTOR inhibitors in advanced renal cell carcinomaNeoplastic disease after liver transplantation: Focus on de novo neoplasmsSkin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repairMetabolic regulation of manganese superoxide dismutase expression via essential amino acid deprivationRtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysemaDistinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cellsMicropublications: a semantic model for claims, evidence, arguments and annotations in biomedical communicationsA comprehensive review of immunosuppression used for liver transplantation.The PIK3CA gene as a mutated target for cancer therapy.Treatment-related mortality with everolimus in cancer patients.Recent advances in the discovery of small molecule mTOR inhibitors.The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.Management of pregnancy in the post-cardiac transplant patient.Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent.Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signalingImmunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A miceInhibitors of the mammalian target of rapamycin.Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Liver transplantation().Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease.The role and value of sirolimus administration in kidney and liver transplantation.Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.Management of the liver transplant patient.Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients.Vector-borne infections in solid organ transplant recipients.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment.Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.The use of everolimus in pediatric liver transplant recipients: first experience in a single center.Converting everolimus to mycophenolate mofetil ameliorated prolonged respiratory syncytial virus infection in a child after heart transplantation.Laryngeal transplantation: research, clinical experience, and future goals.Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.Methionine sulfoximine treatment and carbon starvation elicit Snf1-independent phosphorylation of the transcription activator Gln3 in Saccharomyces cerevisiae.
P2860
Q24612127-A498C03A-C056-4C9F-A3B4-BFFDA398F1EFQ26798306-C85D2DCF-B63E-43E6-9238-C9B49591674DQ26822549-6A52685C-1806-4A1D-A739-9A09E7282BB7Q28384779-6D3B9894-5275-49A7-A513-27CF0546FC36Q28397712-25A73025-28D1-4976-B468-F405CFF1C7D4Q28509199-56CD9B0B-4E0C-43F9-81D9-95C66FE8151BQ28631063-40F70031-A83B-4493-B1DE-8DF242F3C15CQ33602527-803938B8-3B9D-47A3-9EA9-74AF35E1DD89Q33699378-5A458783-98C2-4065-B2C5-723C50792C52Q33699582-CCBF8615-1232-45DC-B871-F106F9FBDE4AQ33852446-888B2F36-6F6A-426C-A016-F3E94E0D42B2Q34283579-EFFADBC7-A2EC-4A4F-8872-2060779BAC8FQ34635688-759E8F4D-6543-49E1-82EB-FAA5F0261D5CQ35047701-FE0D0D32-277A-4ECC-9160-6AC36C8A430AQ35627813-3A171A31-C9CB-416E-85DE-9EB6FAB83294Q35758328-C5599999-9907-4028-B7B1-FC12E9E51753Q35836396-63AFD062-4773-4865-A801-E0AE946971EAQ35849770-2C504E57-B76D-44F3-A90E-20B1BD1FDAC5Q36099427-9C32A882-422D-4103-943D-B63764D61067Q36102839-55E87695-2025-46C1-A328-F7D7116BE8BFQ36183858-1838472B-D85E-4B75-9470-B17CEBBFE007Q36340199-895F0BB3-23B0-4DAB-A80F-8DB570466578Q36549331-0131CF49-36B5-4D38-BF71-C648F2A7F0F8Q36652031-E393EA0E-7BDB-4063-AEF2-BFBBDBEB3C89Q36847294-4F61B53E-7651-49C6-95A5-BD062C551EF4Q37105132-39FA0F7B-89AD-4586-9A87-152590A38C67Q37355472-3ABE52BD-B18D-47C7-8CA5-919E5C2B04B3Q37636100-FC67E8E3-1420-4547-97DD-B802C4721C25Q37842326-B3C17206-6994-48E3-B57F-5A7A5007B73FQ37946501-58BE29E5-EB26-4412-94EE-293177B92D36Q37969834-9592AC09-EE59-4EF7-8DD6-9C286B301648Q38221424-C1EB720E-1672-4528-AB31-7E6E6F6EC2D2Q38858398-E8CD18BE-249E-4826-B8C1-3F0F16A53CC3Q39591754-4712CBF2-3389-46CD-B3D6-365FA84420F8Q39736671-5EAD38B7-CCDE-44F2-9209-D93D2E1ECEC8Q40095420-5C4B5566-6E87-48F7-83CB-60B262BC904AQ40159228-D0B8EEF6-2D49-4341-AFF8-DD2A2E24F281Q40446087-6EB1EA21-841F-4055-BD7C-BA8155C0FDB7Q40706040-BF29D3DF-A8CA-4A75-AB52-40C2DE7E0AB7Q41875347-D5A9144E-2022-4DD9-A97E-84FC89176C0A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
mTOR inhibitors: an overview.
@ast
mTOR inhibitors: an overview.
@en
mTOR inhibitors: an overview.
@nl
type
label
mTOR inhibitors: an overview.
@ast
mTOR inhibitors: an overview.
@en
mTOR inhibitors: an overview.
@nl
prefLabel
mTOR inhibitors: an overview.
@ast
mTOR inhibitors: an overview.
@en
mTOR inhibitors: an overview.
@nl
P2860
P356
P1476
mTOR inhibitors: an overview.
@en
P2093
P2860
P304
P356
10.1053/JLTS.2001.24645
P577
2001-06-01T00:00:00Z